DOI: https://doi.org/10.21203/rs.3.rs-1202475/v1
Background: Glutathione S-transferases (GSTs) genes single-nucleotide polymorphisms (SNPs) have been connected with the susceptibility of nonalcoholic fatty liver disease (NAFLD), but with inconsistent results across the current evidences. The present work was schemed to explore the association between GSTs genes polymorphisms and the NAFLD vulnerability via meta-analysis.
Methods: PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI) and Wanfang were retrieved for eligible literatures previous to March 10, 2021. The odds ratio (OR) of the dichotomic variables and the standardized mean difference of quantitative variables with corresponding 95% confidence intervals (95%CIs) were computed to evaluate the strength of the associations. The quality of included studies were assessed via using Newcastle-Ottawa Scale (NOS).
Results: In total, 7 case-control studies encompassing 804 NAFLD patients and 1362 disease-free controls in this meta-analysis. Ultimately, this analysis included six, five and five studies for GSTM1, GSTT1 and GSTP1 polymorphisms respectively. The pooled data revealed that the GSTs genes single-nucleotide polymorphisms had conspicuous associations with NAFLD susceptibility: for GSTM1, null vs. present, OR=1.46, 95%CI 1.20-1.79, P=0.0002; for GSTT1, null vs. present, OR=1.34, 95%CI 1.06-1.68, P=0.01; for GSTP1, Ile/Val or Val/Val vs. Ile/Ile, OR=1.60, 95%CI 1.23-2.09, P=0.0005.
Conclusion: This work revealed that the GSTM1 null, GSTT1 null and GSTP1-Val genotypes might be related to increased NAFLD susceptibility.
Nonalcoholic fatty liver disease (NAFLD) is gradually considered as the liver disease component of metabolic syndrome, which a risk factor for further development of fatty liver, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma [1]. According to the present data, NAFLD affects 10%-30% of the general population in various countries, which it has been viewed as a huge global health burden [2]. Little is known about the latent mechanism involved in the development and pathogenesis of NAFLD, and yet it is a complicated metabolic process in which both environmental and genetic factors are etiology [3]. At present, genome wide association studies (GWAS) have demonstrated that several conspicuous genetic susceptibility genes such as GSTs, KLF6, GCKR, which had been verified the crutial roles in the disease onset and progression of NAFLD. In resent years, epidemiological studies have shown that GSTs are a multifunctional enzyme in relation to the endogenous toxic metabolites, phase II detoxification of xenobiotics and free radicals [4]. Moreover, the GSTs family acts a significant role in antioxidant defence mechanisms via accelerating detoxification of electrophilic xenobiotics and deactivating a range of endogenous byproduct of oxidative stress [5–8]. So far, studies have confirmed that GST enzymes in possession of eight classes of soluble cytoplasmic isoforms, such as α-(A), ζ-(Z), θ-(T), κ-(K), µ-(M), π-(P), σ-(D), and ω-(O) [9]. In the last few years, GSTT1, GSTM1, and GSTP1 have attracted much ttention. Indeed, the GSTT1, GSTM1, and GSTP1 genes encodes the θ, µ, π class of GST enzymes, and they are located on chromosomes 1p13.3, 22q11.2 and 11q13, respectively [10]. It is reported that GSTT1/GSTM1 deletions (GSTT1/GSTM1 null) could inhibit detoxification of GSTT1/GSTM1 substrates that are either toxicant or carcinogen. Double null genotypes of GSTM1 and GSTT1 might give rise to a complete lack of enzymatic activity [11]. Furthermore, the GSTP1 gene polymorphism is the outcome of a single nucleotide substitution of A to G, which leads to valine instead of isoleucine in the binding site of GSTP1 and alters catalytic activity of enzyme [12, 13].
Several studies have appraised the relationship of GSTs genes SNPs and liver-related diseases. It indicated that the null genotypes of GSTM1/GSTT1 and GSTP1-Val (105) genes SNPs were related to the risk of NAFLD [14–20]. However, these studies yielded varying and divergent results. Accordingly, a meta-analysis was carried out to supply a more accurate and synthetic assessment on the relationship of GSTM1, GSTT1, GSTP1 genes polymorphisms and the NAFLD susceptibility.
Two independent researchers (Ming Qiao and Yi Zhu) searched the PubMed, Web of Science, Cochrane Library, CNKI and Wanfang databases prior to March 10, 2021. The searching strategy of PubMed was exhibited as follows: (“nonalcoholic fatty liver disease [Mesh]” OR “non-alcoholic fatty liver disease” OR “NAFLD” OR “non-alcoholic steatohepatitis” OR “NASH”) AND (“GSTT1” OR “GSTM1” OR “GSTP1” OR “glutathione S-transferase” [Mesh]) AND (Single Nucleotide Polymorphism[Mesh] OR Variant OR SNP OR Polymorphism OR mutant OR mutation OR variation). No language restriction was set.
Original studies were incorporated into this analysis in the light of the following inclusion criteria: (i) case-control studies; (ii) study investigated the associations of GSTs polymorphisms and NAFLD predisposition; (iii) NAFLD is diagnosed by pathology or ultrasound; (iv) control subjects were disease-free individuals; (v) detailed genotype data can be calculated for ORs and 95% CIs. Correspondingly, reviews, conference abstracts, commentary articles, letters to editor, animal studies, unpublished data, case reports, as well as family-based studies were excluded.
The Newcastle-Ottawa Scale (NOS) was performed to evaluate the methodological quality of included studies by two independent investigators (Ming Qiao and Yi Zhu). The NOS is composed of three aspects, namely selection, comparability and exposure. Each study could receive 0 to 9 scores. Nevertheless, studies with≥6 scores were regarded as high-quality studies. Disagreement was resolved by discussion.
The extracted information contained the name of first author, year of publication, country, ethnicity and gender of enrolled subjects, numbers of NAFLD and control subjects, diagnostic methods of NAFLD, genotyping of enrolled subjects and Hardy-Weinberg equilibrium (HWE) results. Ming Qiao and Yi Zhu extracted the information independently.
The control participants of incorporated studies were estimated via HWE [21]. Summary ORs with 95% CIs were computed to specifically evaluate the relationship of GSTs polymorphisms and the NAFLD susceptibility. Cochran's Q-test and I2 test were applied to appraise the between-study heterogeneity [22]. The random-effect model was employed to calculate merged ORs if P<0.1, I2 >50%. If not, the fixed-effect model was utilized for data synthesis [23]. Sensitivity analysis was performed as well to assess the stability of all incorporated studis via the leave-one-out method. When the included studies were more than 10, funnel plot was employed to valuated the publication bias [24]. On the contrary, less than 10 studies are not required. All analyses were done using RevMan 5.3 software.
Primary search of electronic databases retrieved 41 potentially relevant publications: 17 from PubMed, 20 from Web of Science, 0 from Cochrane library, 1 from CNKI and 3 from Wanfang. No additional records were acquired from other sources. And then 25 studies remained after removing duplicated articles. Subsequently, a total of 9 irrelevant articles were excluded on the basis of titles and abstracts screening. After applying inclusion and exclusion criteria, 7 unrelated articles, 1 conference abstract were removed and 1 full-text article was not available. Ultimately, seven studies went into the process of meta-analysis. Overall, a flowchart summarizing the procedure of literature identification was illustrated in Fig. 1.
The studies were performed in Italy [14], Japanese [15, 17], Iran [16,18] and Ukraine [19, 20]. In total, seven studies encompassing 804 case and 1362 control participants were analyzed in current analysis. For GSTM1, GSTT1 and GSTP1 genes SNPs, there were six, five and five studies ultimately incorporated, respectively. They were all case-control designed and published between 2008 and 2020 (Table 1). In addition, studies with≥6 scores were regarded as high-quality studies according to evaluation of methodological quality (Table 2).
Table 1
Main characteristics of the included studies.
|
|
|
|
|
|
|
Case |
Control |
|
||
Study |
Year |
Country |
Ethnicity |
Gender |
Means of diagnosis |
Sample size |
null |
present |
null |
present |
HWE |
GSTM1 |
|
|
|
|
|
|
|
|
|
|
|
Luca M |
2014 |
Italy |
Caucasian |
both |
Ultrasonography |
234/349 |
145 |
147 |
187 |
172 |
0.54 |
Masaharu H |
2008 |
Japanese |
Asian |
both |
Ultrasonography |
69/184 |
40 |
29 |
84 |
100 |
< 0.05 |
Mohammad H |
2012 |
Iran |
Asian |
both |
NA |
83/93 |
48 |
35 |
36 |
57 |
0.015 |
Kentaro O |
2013 |
Japanese |
Asian |
both |
Ultrasonography |
130/566 |
74 |
56 |
277 |
289 |
0.12 |
Tamandani D |
2011 |
Iran |
Asian |
NA |
NA |
80/80 |
11 |
69 |
7 |
73 |
0.3 |
Vasyl P |
2020 |
Ukraine |
Caucasian |
both |
Ultrasonography |
104/45 |
52 |
52 |
23 |
22 |
NA |
GSTT1 |
|
|
|
|
|
|
|
|
|
|
|
Luca M |
2014 |
Italy |
Caucasian |
both |
Ultrasonography |
234/349 |
75 |
217 |
83 |
276 |
0.45 |
Masaharu H |
2008 |
Japanese |
Asian |
both |
Ultrasonography |
69/184 |
37 |
32 |
85 |
99 |
0.09 |
Mohammad H |
2012 |
Iran |
Asian |
both |
NA |
83/93 |
2 |
81 |
0 |
93 |
0.221 |
Kentaro O |
2013 |
Japanese |
Asian |
both |
Ultrasonography |
130/566 |
61 |
69 |
249 |
317 |
0.49 |
Vasyl P |
2020 |
Ukraine |
Caucasian |
both |
Ultrasonography |
104/45 |
18 |
86 |
6 |
39 |
NA |
GSTP1 |
|
|
|
|
|
|
Ile/Ile |
Ile/Val or Val/Val |
Ile/Ile |
Ile/Val or Val/Val |
|
Masaharu H |
2008 |
Japanese |
Asian |
both |
Ultrasonography |
69/184 |
49 |
20 |
142 |
42 |
0.14 |
Mohammad H |
2012 |
Iran |
Asian |
both |
NA |
83/93 |
29 |
54 |
53 |
40 |
0.003 |
Kentaro O |
2013 |
Japanese |
Asian |
both |
Ultrasonography |
130/566 |
89 |
41 |
424 |
142 |
0.13 |
Tamandani D |
2011 |
Iran |
Asian |
NA |
NA |
80/80 |
9 |
71 |
10 |
70 |
0.1 |
Prysyazhnyuk VP |
2017 |
Ukraine |
Caucasian |
NA |
NA |
104/45 |
47 |
57 |
28 |
17 |
NA |
Table 2
Quality assessment of included studies based upon the Newcastle-Ottawa Scale (NOS)
Item/Study |
Luca M |
Masaharu H |
Mohammad H |
Kentaro O |
Tamandani D |
Vasyl P |
Prysyazhnyuk VP |
2014 |
2008 |
2012 |
2013 |
2011 |
2020 |
2017 |
|
Selection |
|
|
|
|
|
|
|
Adequate definition of cases |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Representativeness of cases |
1 |
1 |
1 |
1 |
1 |
0 |
0 |
Selection of control subjects |
1 |
0 |
0 |
0 |
0 |
1 |
0 |
Definition of control subjects |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Comparability |
|
|
|
|
|
|
|
Control for important factor or additional factor |
1 |
1 |
1 |
1 |
1 |
2 |
1 |
Exposure |
|
|
|
|
|
|
|
Exposure assessment |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Same method of ascertainment for all subjects |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Non-response rate |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Total score |
8 |
7 |
7 |
7 |
7 |
8 |
6 |
In total of six studies including 700 NAFLD patients and 1317 controls for GSTM1 gene polymorphism. The fixed-effects model was employed for data analysis on account of the heterogeneity in between-study was not remarkable. It revealed that GSTM1 was appreciably connected with the NAFLD vulnerability (null vs. present, OR=1.46, 95%CI: 1.20-1.79, P=0.0002; Fig. 2).
Overall, five researches containing 620 NAFLD and 1237 healthy subjects for GSTT1 to perform data analysis. There was no heterogeneity amidst studies for GSTT1 (P=0.72, I2=0%). So the fixed-effects model was performed for data analysis. The pooled data indicated there was a noticeable association between the single nucleotide polymorphism of GSTT1 and the NAFLD susceptibility (null vs. present, OR=1.34, 95%CI: 1.06-1.68, P=0.01; Fig. 3).
In total of five studies with 466 cases and 968 controls were used for data pooled. The fixed-effect model was carried out to estimate the association of GSTP1 gene polymorphism and the NAFLD risk by virtue of no heterogeneity among studies (P=0.47, I2=0%). The results indicated a obvious association between GSTP1 gene polymorphism and NAFLD susceptibility (Ile/Val or Val/Val vs. Ile/Ile, OR=1.60, 95%CI 1.23-2.09, P=0.0005; Fig. 4).
After the omission of an individual study, the recalculated P-value, ORs and 95%CIs did not change substantially. Therefore, the outcomes were considered to be statistically robust and reliable. The funnel plot for assessment of publication bias was not implemented on account of less than 10 researches.
Despite the specific pathological mechanism of NAFLD still needs to be explored. Nevertheless, research increasingly revealed that genetic predisposition plays an crucial intrinsic role in the occurrence and development of NAFLD. In addition, SNPs in human might be one of the critical steps to disclose the genetic factor for NAFLD pathogenesis. With further research, GSTs genes as a genetic factor have obtained increasing attention over current years. So far, the present researches have been implemented concerning the relationship of GSTM1, GSTT1 and GSTP1 genes polymorphism and the NAFLD vulnerability with inconsistent conclusions. This inconsistency might be caused by factors like limited sample sizes, confounding factors, as well as clinical heterogeneity of NAFLD. Therefore, we collected the existing evidence and looked into the associations of GSTs genes SNPs and the NAFLD vulnerability via meta-analysis, which could combine data from individual studies, examine and explain the heterogeneity, and increase the statistical power. In conclusion, the merged data suggested a significant correlation between GSTM1, GSTT1 and GSTP1 genes SNPs and the NAFLD vulnerability. Of note, the recalculated P-value, ORs and 95%CIs did not change substantially after the omission of an individual study.
In a word, we performed a meta-analysis of 7 case-control studies that satisfied the inclusion criteria. It should be noted that the current comprehensive analysis was more necessary and meaningful owing to the conclusions of qualified case-control studies are conflicting and contradictory. In this work, it demonstrated that the frequency of GSTM1 null, GSTT1 null and GSTP1-Val allele genotypes in NAFLD patients was remarkably higher than that in healthy subjects. Namely, these genotypes have a significantly increased risk for NAFLD. Furthermore, the outcomes of the meta-analysis were considered to be statistically robust and reliable according to the sensitivity analysis.
GSTs are enzymes in the second-stage detoxification system, which can not only catalyze reduced glutathione sulfhydryl groups, but also neutralize lipid and DNA oxidation products, and have protective effects against endogenous oxidative stress and exogenous toxins [25–26]. Among them, GSTT1, GSTM1 and GSTP1 have garnered considerable attention from various research teams around the world in the recent decade [27]. Several investigations have disclosed that homozygous deletion of GSTM1 and GSTT1 genes (GSTM1 null and GSTT1 null) were connected with lack of relevant GST isoenzyme synthesis and augmented the susceptibility of genetic damage [28–29]. Furthermore, the double null genotypes of GSTT1 and GSTM1 genes could decline the activity of sulfhydryl binding so as to induce insufficient activity of detoxification in the body [30, 31]. GSTP1 gene polymorphism is the outcome of a single nucleotide substitution of A to G, which leads to valine instead of isoleucine in the binding site of GSTP1 and alters catalytic activity of enzyme [32, 33]. Previous reports also suggested that GSTM1/GSTT1 null or GSTP1-Val genotypes were remarkably associated with the vulnerability of hepatis B virus, hepatocellular carcinoma, alcoholic cirrhosis, and NAFLD [34–39]. Moreover, the GSTM1 null genotype was reported to be more common in NAFLD patients than in controls, and GSTP1-Val was proved to be a hazard for NAFLD vulnerability in the Iranian population [40].
Up to now, this is the first synthetical study on the relationship between GSTs polymorphisms and NAFLD vulnerability. There were several strengths in this study. First, to gather a maximum amount of relevant literature, a comprehensive search strategy was adopted to retrieve eligible studies in both English and Chinese databases. Besides, the methodological quality of studies was evaluated via NOS, which allowed for the judgment of potential risk of bias. According to the NOS, all eligible studies were of high methodological quality. Furthermore, sensitivity analyses were carried out in this study, which guaranteed the reliability of the findings.
Nevertheless, there still existed several drawbacks should be acknowledged. First, only seven studies were included, the statistical power was limited, and subgroup analyses were not carried out because of the limited degree of freedom. Second, the absence of HWE in individual studies may lead to information bias. Third, We ignored the synergistic effect of polymorphism at other sites of NAFLD because only three loci in the GST gene were studied in association with susceptibility to NAFLD. Thus, interactions between these loci and genes may result in concealing or amplifying the actual function of individual loci or genes. Leave aside these drawbacks, this study is the first to provide a more accurate and powerful evidence on the association between GSTM1, GSTT1 and GSTP1 genes polymorphisms and NAFLD vulnerability.
In brief, it revealed that GSTM1 null, GSTT1 null and GSTP1-Val genotypes were appreciably associated with augmented risk of NAFLD vulnerability. Concerning limitations of this study, it is necessary to confirm the present findings by complementary studies with larger sample size.
GSTs: Glutathione S-transferases; HWE: Hardy-Weinberg equilibrium; NAFLD: Nonalcoholic fatty liver disease; NOS: Newcastle-Ottawa Scale; OR: Odds ratio; 95%CI: 95% confdence interval
Not applicable.
Ming Qiao conceived of the idea and wrote the manuscript. The literature retrieval and data analysis by Yi Zhu. The authors read and approved the final manuscript.
This article was supported by the Natural Science Foundation of Xinjiang Uygur Autonomous Region, China.
All the data generated in the present research is contained in this manuscript.
Not applicable.
Not applicable.
The authors declare that they have no competing interests.
1Department of pharmacy, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China